Literature DB >> 10854837

Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing.

R J Lamb1, T U Järbe, A Makriyannis, S Lin, A Goutopoulos.   

Abstract

We examined the effects of Delta 9-tetrahydrocannabinol (Delta 9-THC), (R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide ((R)-methanandamide, AM 356), SR 141716, and d-amphetamine on fixed-ratio (FR) responding maintained by food in rats before and during daily dosing with Delta 9-THC. Rats responded under a FR 10 schedule of food reinforcement. Cumulative dose-response curves for the various drugs were determined before and during daily Delta 9-THC administration. All four drugs dose-dependently decreased responding both before and during daily dosing with Delta 9-THC (18 mg/kg/day). The dose-response curves for both Delta 9-THC and (R)-methanandamide were shifted to the right with daily dosing with Delta 9-THC, indicating tolerance to the effects of Delta 9-THC and cross-tolerance to the effects of (R)-methanandamide. The doses of d-amphetamine examined produced similar effects both before and during daily dosing with Delta 9-THC. The effects of SR 141716 were not consistently altered by daily Delta 9-THC administration. These results indicate that tolerance develops to the effects of Delta 9-THC, when Delta 9-THC is administered repeatedly. These results also indicate that cross-tolerance to (R)-methanandamide develops with repeated Delta 9-THC administration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854837     DOI: 10.1016/s0014-2999(00)00318-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.

Authors:  Michael Z Leonard; Shakiru O Alapafuja; Lipin Ji; Vidyanand G Shukla; Yingpeng Liu; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman; Brian D Kangas
Journal:  J Pharmacol Exp Ther       Date:  2017-09-25       Impact factor: 4.030

2.  Cannabinoid Antagonist Drug Discrimination in Nonhuman Primates.

Authors:  Brian D Kangas; Ani S Zakarian; Kiran Vemuri; Shakiru O Alapafuja; Shan Jiang; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2019-10-22       Impact factor: 4.030

3.  Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.

Authors:  Torbjörn U C Järbe; Roger S Gifford; Alexandros Makriyannis
Journal:  Eur J Pharmacol       Date:  2010-09-18       Impact factor: 4.432

4.  Tolerance to chronic delta-9-tetrahydrocannabinol (Δ⁹-THC) in rhesus macaques infected with simian immunodeficiency virus.

Authors:  Peter J Winsauer; Patricia E Molina; Angela M Amedee; Catalin M Filipeanu; Robin R McGoey; Dana A Troxclair; Edith M Walker; Leslie L Birke; Curtis Vande Stouwe; Jessica M Howard; Stuart T Leonard; Joseph M Moerschbaecher; Peter B Lewis
Journal:  Exp Clin Psychopharmacol       Date:  2011-04       Impact factor: 3.157

5.  Cannabinoid conditioned reward and aversion: behavioral and neural processes.

Authors:  Jennifer E Murray; Rick A Bevins
Journal:  ACS Chem Neurosci       Date:  2010-03-10       Impact factor: 4.418

6.  Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.

Authors:  Brian D Kangas; Marcus S Delatte; V Kiran Vemuri; Ganesh A Thakur; Spyridon P Nikas; Kumara V Subramanian; Vidyanand G Shukla; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2013-01-03       Impact factor: 4.030

7.  Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure.

Authors:  Brett C Ginsburg; Lenka Hruba; Armia Zaki; Martin A Javors; Lance R McMahon
Journal:  Drug Alcohol Depend       Date:  2014-03-19       Impact factor: 4.492

8.  Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs.

Authors:  Rajeev I Desai; Ganesh A Thakur; V Kiran Vemuri; Shama Bajaj; Alexandros Makriyannis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2012-11-29       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.